International Journal of Cancer最新文献

{"title":"Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade.","authors":"Coline Ducrot, Derek Dinart, Mathilde Reich, Max Piffoux, Maeva Bonneau, Mathieu Larroquette, Simon Nannini, Juliane Berchoud, Helène Bellio, Gregory Cherrier, Berengère Narciso, Axel Le Cesne, Emmanuelle Bompas, Justine Gantzer, Thibaud Valentin, Philippe Anract, Sixtine de Percin, Pascaline Boudou-Rouquette, Gonzague de Pinieux, Francois Gouin, Mehdi Brahmi, Carine Bellera, Maud Toulmonde","doi":"10.1002/ijc.70023","DOIUrl":"https://doi.org/10.1002/ijc.70023","url":null,"abstract":"<p><p>Metastatic chondrosarcoma (MCS) has a poor prognosis, and treatment options are scarce in this rare disease. This multicenter observational study provides real-world data on treatment patterns of patients with MCS in France. Treatment characteristics, outcomes in terms of time to next treatment (TTNT) and overall survival (OS), and prognostic factors of patients ≥12-year-old treated for a MCS in nine French reference network centers were retrieved from the French Sarcoma Group prospective database. From 2008 to 2018, 127 patients with MCS were included, 31 were metastatic from diagnosis (synchronous cohort), 89 had a metastatic relapse, and 7 had locally advanced unresectable disease, of whom 4 developed secondary metastases (metachronous cohort). Median age at diagnosis was 61 years (14-90), 58.9% of patients received a systemic treatment with a median of 2 lines (1-6), 40.3% had a locoregional procedure on metastasis, and 9.7% of patients participated in a clinical trial at least once in the metastatic setting. Median OS from metastatic diagnosis was 12.7 months [95%CI 8.2, 14.9], without significant difference between the metachronous and synchronous cohorts. Median TTNT was 4.6 months [95%CI 3.0, 5.9], 3.4 months [95%CI 2.7, 4.8], and 3.4 months [95%CI 2.0, 7.9] in first, second, and third lines, respectively. In MCS, benefits of chemotherapies are very limited. Tyrosine kinase inhibitors such as regorafenib or pazopanib show some activity from first line. Locoregional treatment of metastasis is associated with survival and should be proposed when feasible. Inclusion in clinical trials should be prioritized.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144705895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of long-term survival in childhood cancer patients using cancer registry data from eastern China: Period analysis outperforms traditional analysis.","authors":"Xin Bing, Qiqi Lei, Liangyou Wang, Xiaojiao Zhao, Xukai Chen, Luyao Zhang, Asta Försti, Jun Yang, Tianhui Chen","doi":"10.1002/ijc.70060","DOIUrl":"https://doi.org/10.1002/ijc.70060","url":null,"abstract":"<p><p>This study systematically evaluated whether period analysis outperforms traditional cohort and complete analyses in estimating 5-year relative survival (RS) for childhood cancer patients using data from nine cancer registries in Taizhou, Eastern China (2009-2018). Analyses included patients under 15 years diagnosed with childhood cancers, with 5-year RS estimates from cohort, complete, and period methods compared against observed actual survival (2014-2018: 70.1%). Accuracy and robustness were assessed via deviation value (DV) and standard error (SE). Cohort analysis yielded a 5-year RS of 55.8% (DV: -14.3%, SE: 2.4), complete analysis 61.1% (DV: -9.0%, SE: 1.7), and period analysis 68.2% (DV: -1.9%, SE: 2.1). Stratified evaluations by sex, region, age at diagnosis, and cancer types confirmed period analysis as the most accurate (lowest DV across subgroups) while complete analysis showed the smallest SE values, indicating superior robustness. Cohort analysis performed the worst in both accuracy and robustness. This study is the first in China to validate that period analysis offers superior accuracy in estimating 5-year RS for childhood cancer patients overall and across various stratifications compared to cohort and complete analyses. Findings underscore the utility of period analysis in generating timely survival estimates to inform early detection strategies and cancer control policies, offering critical methodological support for advancing pediatric oncology outcomes assessment in China.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological evaluation of a glucose-based boron carrier as a potential agent for boron neutron capture therapy.","authors":"Surachet Imlimthan, Katayun Bahrami, Henna Pehkonen, Alessia Centanni, Ahmed B Montaser, Arina Värä, Jelena Matović, Heidi Liljenbäck, Tatsiana Auchynnikava, Kristiina M Huttunen, Anne Roivainen, Anu J Airaksinen, Filip S Ekholm, Outi Monni, Jarkko Rautio, Mirkka Sarparanta","doi":"10.1002/ijc.70054","DOIUrl":"https://doi.org/10.1002/ijc.70054","url":null,"abstract":"<p><p>Boron neutron capture therapy (BNCT) is an innovative radiation oncology approach that targets tumors selectively, minimizing damage to healthy tissues through high-linear-energy-transfer particles released during the boron neutron capture reaction. Current boron carriers like sodium mercaptoundecahydrododecaborate (BSH) and L-p-boronophenylalanine (BPA) face limitations in specificity and solubility. Our recently developed 6-O-(o-carboranylmethyl)-d-glucopyranose (B-Glc) shows promise as an alternative, demonstrating strong interactions with glucose transporters in human head and neck squamous cell carcinoma (HNSCC) CAL 27 cells in vitro. This study aims to extend in vitro investigations to three additional patient-derived human HNSCC cell lines (UT-SCC-14, UT-SCC-28, and UT-SCC-42B) and to further evaluate in vivo pharmacokinetics in selected HNSCC tumor xenografts. The B-Glc showed superior uptake and favorable kinetic parameters compared to BPA and BSH in all tested cell lines. Initial positron emission tomography imaging using [¹⁸F]fluoro-2-deoxy-d-glucose ([¹⁸F]FDG) radiotracer confirmed increased glucose uptake in CAL 27 and UT-SCC-14 tumors in vivo, supported by glucose transporter 1 (GLUT1) expression observed in tumor section immunohistochemistry. Biodistribution studies of the B-Glc (75 mg/kg dose) revealed no significant impact of blood glucose levels on tumor uptake, with peak boron accumulation at 15-30 min post-injection, comparable uptake to the clinical BPA-fructose complex (400 mg/kg dose) performance at 60 min, achieving the required tumor boron concentration (>20 ppm) for effective BNCT. Overall, this study underscores an advancement in targeted BNCT, highlighting B-Glc as an effective GLUT1-targeting carrier for enhanced therapeutic outcome in HNSCC and the potential to use [¹⁸F]FDG as a companion diagnostic for the glucoconjugate.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The interplay between oxidative stress and epigenetic reprogramming in cancer.","authors":"Xuejiao Ma, Wei Fan, Tao Zhang, Li Luo, Kui Wang","doi":"10.1002/ijc.70058","DOIUrl":"https://doi.org/10.1002/ijc.70058","url":null,"abstract":"<p><p>Oxidative stress and epigenetic reprogramming are two crucial characteristics of cancer cells. Oxidative stress is defined as an imbalance between intracellular oxidation and antioxidation, while epigenetic modifications represent heritable alterations in gene expression without altering the DNA sequence. During the past decades, mounting evidence has suggested that oxidative stress profoundly impacts gene expression by regulating epigenetic events, including DNA methylation, histone modifications, and non-coding RNAs. In turn, epigenetic modifications can also influence oxidative stress through methylating mitochondrial DNA/RNA or regulating the expression of genes in mitochondrial electron transport chain (Mito-ETC) components and antioxidant systems. In this review, we summarize the crosstalk mechanisms between oxidative stress and epigenetic reprogramming, with an emphasis on their reciprocal regulation involved in carcinogenesis and cancer immune escape.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).","authors":"Yuki Matsubara, Toshiki Masuishi, Waki Hosoda, Hidekazu Hirano, Saori Mishima, Hiroyuki Takahashi, Tomoyuki Otsuka, Kenta Kawasaki, Takeshi Kawakami, Kazuhiro Yanagihara, Takaya Shimura, Masato Komoda, Kozue Murayama, Keiko Minashi, Yoshiyuki Yamamoto, Yudai Shinohara, Shinichi Nishina, Nobuyuki Musha, Kyoko Kato, Kentaro Kawakami, Katsunori Shinozaki, Kenji Tsuchihashi, Takayuki Ando, Yosuke Kito, Akitaka Makiyama, Seiichiro Mitani, Kaori Hino, Naoki Izawa, Isao Oze, Kei Muro","doi":"10.1002/ijc.70053","DOIUrl":"https://doi.org/10.1002/ijc.70053","url":null,"abstract":"<p><p>No standard second-line chemotherapy has been established for gastrointestinal neuroendocrine carcinoma (NEC). This study aimed to determine whether ramucirumab (RAM) is a treatment candidate in this setting. We retrospectively collected data from patients with gastric and colorectal NEC who received second-line chemotherapy following platinum-based chemotherapy. The pathological diagnosis of NEC was confirmed centrally according to the World Health Organization 2019 classification. We compared the clinical outcomes between second- or later-line chemotherapy in the RAM group and second-line chemotherapy in the non-RAM group. One-hundred patients diagnosed with NEC by central pathological review were studied. The RAM and non-RAM groups included 44 (gastric/colorectal cancer, 34/10) and 56 (37/19) patients, respectively. In the RAM group, 68% of patients received RAM as second-line chemotherapy. RAM was most frequently combined with weekly paclitaxel for gastric NEC and FOLFIRI for colorectal NEC. The RAM group showed better trends in overall survival and progression-free survival than the non-RAM group, with a median of 9.0 versus 5.6 months and 4.3 versus 1.8 months, respectively (hazard ratios [HR]: 0.75 [95% CI: 0.45-1.28] and 0.45 [0.27-0.75]). Efficacy was more pronounced in gastric NEC (PFS HR: 0.32, OS HR: 0.56) compared to colorectal NEC (PFS HR: 0.82, OS HR: 1.47). The objective response rate was significantly higher in the RAM group (44%) than in the non-RAM group (6%), with notably higher responses observed in patients receiving paclitaxel plus RAM (62%). This study suggested that RAM-containing chemotherapy, especially paclitaxel plus RAM for gastric NEC, seems promising and should be further investigated.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rewriting the MASLD-associated hepatocellular carcinoma script: Targeting epigenetics and metabolism.","authors":"Chiara Aiello, Eric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia-Sancho, Andrea Baiocchini, Simone Carotti","doi":"10.1002/ijc.70047","DOIUrl":"https://doi.org/10.1002/ijc.70047","url":null,"abstract":"<p><p>Abnormal epigenetic patterns are crucial for the progression of metabolic-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC) development. Recent research focused on the interplay between epigenetics and altered metabolic pathways in HCC from MASLD, suggesting that the reversibility of epigenetic changes offers potential for new therapeutic strategies. However, identifying effective epigenetic targets remains challenging due to the diverse etiologies of HCC. Targeting metabolic reprogramming, MASLD-associated HCC shows promise in reducing lipid anabolism. In this context, a more comprehensive understanding of metabolomic changes closely tied to druggable epigenetic modifications is of utmost importance. This review provides a concise summary of the key factors driving hepatocarcinogenesis in MASLD and delves deeper into the epigenetic mechanisms. Finally, we aim to present an overview of the primary mechanisms concerning the intricate bidirectional interplay between the metabolome and epigenetic modifications in MASLD-associated HCC, along with therapeutic strategies specifically targeting epigenetics and metabolomic alterations.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy.","authors":"Max Kraemer, Naita M Wirsik, Hakan Alakus, Hans A Schloesser, Hans Fuchs, Wolfgang Schroeder, Christiane J Bruns, Su Ir Lyu, Friederike Baehr, Thomas Zander, Alexander Quaas","doi":"10.1002/ijc.70048","DOIUrl":"https://doi.org/10.1002/ijc.70048","url":null,"abstract":"<p><p>Oesophagogastric junction and gastric adenocarcinoma (OGA) are associated with high mortality rates, with 5-year survival rates below 50% in the curative setting. This study evaluates the efficacy of adjuvant chemotherapy (a chemotherapy regimen consisting of docetaxel, oxaliplatin, leucovorin and 5-fluorouracil [FLOT]) in patients with low tumour regression grades (TRG) following neoadjuvant FLOT (>10% viable tumour cells in surgical specimen, TRG 2/3 analogue Becker's classification). Data from all patients who had undergone ≥3 cycles of neoadjuvant FLOT with R0 resection and TRG 2/3 in surgical specimen, diagnosed between 2017 and 2020 at the University of Cologne (n = 134), were analyzed. Patients were categorised into three groups based on the administration of postoperative FLOT: 'FLOT complete' (four cycles), 'FLOT incomplete' (one to three cycles) and 'no FLOT' (0 cycles). Progression-free survival (PFS) and overall survival (OS) were compared. There is a statistically significant PFS advantage for the 'FLOT complete' group compared to 'no FLOT' (p = .028) in the total patient cohort and a tendency for an OS benefit. In the subgroup of patients with lymph node metastasis in surgical specimen (ypN+ cohort, n = 91), the PFS advantage of 'FLOT complete' was diminished and statistically no longer significant, and there is no OS benefit for these patients. However, multivariate analysis confirmed a significant PFS benefit for 'FLOT complete' both in the total cohort (p = .011) and in ypN+ patients (p = .018). These findings suggest that full adjuvant FLOT is beneficial even for OGA patients with low tumour regression; however, its efficacy appears reduced in those with lymph node metastasis, warranting further investigation into individualising treatment strategies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.","authors":"Fei Huang, Huiqin Jiang, Minna Shen, Chunyan Zhang, Yu Chen, Baishen Pan, Beili Wang, Wei Guo, Wenjing Yang","doi":"10.1002/ijc.70055","DOIUrl":"https://doi.org/10.1002/ijc.70055","url":null,"abstract":"<p><p>Altered metabolites are pivotal in hepatocellular carcinoma (HCC) development. This study employed untargeted metabolomic analysis to identify novel biomarkers for early HCC detection and explore their functions. Plasma samples were collected from 138 HCC patients, 69 patients with benign hepatic lesions, and 35 healthy donors. These samples were divided into a discovery set of 171 and a validation set of 71, and analyzed using ultra high performance liquid chromatography mass spectrometry. Through paired t-tests and orthogonal partial least-squares discriminant analysis, nine metabolites with significant predictive value were selected out and incorporated into a model for HCC diagnosis. Area under curves for the discovery set, the validation set, and all samples were 0.97, 0.95, and 0.96, respectively. The satisfactory diagnostic performance was maintained regardless of the China liver cancer (CNLC) staging. Additionally, this model demonstrated better diagnostic performance than alpha-fetoprotein (AFP) when comparing HCC to controls in different CNLC stages. The metabolite pathway enrichment analysis showed that alterations in plasma bile acids were associated with cirrhosis. Univariate and multivariate analyses indicated that the ratio of L-Serine and Sarcosine was an independent predictor for microvascular invasion (MVI). An integrated analysis of metabolomic data with transcriptomic data from the Cancer Genome Atlas revealed that the low expression of alanine glyoxylate aminotransferase (AGXT) and glycine amidinotransferase (GATM) was more likely related to MVI. To sum up, our research findings may offer valuable insights into HCC metabolic alterations and contribute to a better characterization of HCC.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144688477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response.","authors":"Andrea Galluzzo, Martina Maffezzini, Maria Luisa Fumagalli, Irene Sambruni, Silvia Musio, Monica Patanè, Rosina Paterra, Erika Salvi, Manuel Facciolla, Micaela Milani, Marco Schiariti, Luca Mattei, Alessandra Rossi, Marica Eoli, Luigi Poliani, Antonio Silvani, Bianca Pollo, Laura Fariselli, Natalia Di Ianni, Serena Pellegatta","doi":"10.1002/ijc.70038","DOIUrl":"https://doi.org/10.1002/ijc.70038","url":null,"abstract":"<p><p>Immunosuppressive myeloid cells, such as microglia and macrophages, play a key role in mediating resistance to immunotherapy in glioblastoma patients. Bulk RNA sequencing analysis revealed elevated expression of Klotho (Kl) in gliomas derived from irradiated glioma-bearing mice. Klotho, which encodes an anti-aging protein, was found to be upregulated in glioma-associated microglia/macrophages (GAMs) exhibiting an M1 pro-inflammatory phenotype. This upregulation appeared to enhance the antitumor efficacy of a combination of radiotherapy and dendritic cell (DC) immunotherapy. Furthermore, transcript levels of KL in tumor specimens and corresponding serum levels in glioblastoma patients undergoing DC immunotherapy were correlated with favorable prognostic outcomes and improved treatment responses. Given its expression in human M1-like GAMs, serum KL levels can offer valuable insights into the immune microenvironment and hold clinical significance as a peripheral biomarker. These findings highlight the pivotal role of Klotho as a prognostic biomarker for predicting responses to immunotherapy, with potential applications for monitoring tumor progression or regression through changes in serum levels.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study.","authors":"Yen Thi-Hai Pham, Renwei Wang, Jaideep Behari, Guo-Chong Chen, Rob M van Dam, Jian-Min Yuan, Hung N Luu","doi":"10.1002/ijc.70057","DOIUrl":"https://doi.org/10.1002/ijc.70057","url":null,"abstract":"<p><p>The plant-based dietary indices (PDIs), which include the healthy and unhealthy plant-based dietary indices, have recently been developed by taking into account the quantity of plant versus animal foods and the quality of plant foods. Data on the association between PDI and hepatocellular carcinoma (HCC) risk are sparse. We, therefore, prospectively evaluated the associations for PDI, healthy PDI (hPDI) and unhealthy PDI (uPDI) with HCC risk. We used data from the Singapore Chinese Health Study, a prospective cohort study of 63,275 participants aged 45-74 in Singapore who were recruited during the 1993-1998 period. PDI, hPDI, and uPDI were derived from the semi-quantitative food frequency questionnaire at baseline. The incident cases of HCC were identified through record linkage with the Singapore Cancer Registry. Cox proportional hazard regression method was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for HCC in relation to PDI, hPDI, and uPDI. After 17.6 years of follow-up with 819,573 person-years, we identified 561 incident HCC cases. There was an inverse association for HCC risk with PDI (HR_{per-SD increment} = 0.87, 95% CI: 0.79-0.95; P_trend = 0.009) and hPDI (HR_{per-SD increment} = 0.86, 95% CI: 0.79-0.94; P_trend = 0.002). This inverse association was similar for HBsAg-negative and HBsAg-positive HCC risk. No association was found between uPDI and HCC risk. In summary, the overall PDI and hPDI were associated with lower risk of HCC in the Chinese Singaporeans. Our findings inform dietary targets for HCC prevention and control programs, particularly in Asian populations.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144666657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}